Janux Therapeutics Inc’s filing revealed that its Chief Business Officer Meyer Andrew Hollman unloaded Company’s shares for reported $0.11 million on May 01 ’25. In the deal valued at $32.03 per share,3,333 shares were sold. As a result of this transaction, Meyer Andrew Hollman now holds 82,139 shares worth roughly $1.99 million.
Then, ANDREW MEYER bought 3,333 shares, generating $110,656 in total proceeds.
Before that, Meyer Andrew Hollman sold 3,334 shares. Janux Therapeutics Inc shares valued at $100,020 were divested by the Chief Business Officer at a price of $30.00 per share. As a result of the transaction, Meyer Andrew Hollman now holds 82,139 shares, worth roughly $1.99 million.
H.C. Wainwright reiterated its Janux Therapeutics Inc [JANX] rating to a Buy in a research note published on December 03, 2024; the price target was $70. A number of analysts have revised their coverage, including BTIG Research’s analysts, who remained covering the stock and in early December has reiterated a ‘”a Buy”‘ rating for it. Leerink Partners began covering JANX with “an Outperform” recommendation on November 22, 2024. UBS started covering the stock on October 24, 2024. It rated JANX as “a Buy”.
Price Performance Review of JANX
On Monday, Janux Therapeutics Inc [NASDAQ:JANX] saw its stock fall -0.45% to $24.17. Over the last five days, the stock has lost -7.25%. Janux Therapeutics Inc shares have fallen nearly -54.86% since the year began. Nevertheless, the stocks have fallen -49.09% over the past one year.
How much short interest is there in Janux Therapeutics Inc?
A steep rise in short interest was recorded in Janux Therapeutics Inc stocks on 2025-04-30, dropping by -0.45 million shares to a total of 9.65 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 10.1 million shares. There was a decline of -4.63%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 06, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
